Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ATH.AX

STRONG SELL

Alterity Therapeutics Limited · Healthcare · Australia · $90M · Avg Vol: $73K/d

15
StockRank
Q
38
V
30
M
29
P/E (TTM)
—
ROE
-47.0%
D/E
0.0x
Dividend %
—
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →

COMPANY DESCRIPTION

Alterity Therapeutics Limited develops disease-modifying therapies for neurodegenerative diseases, with its lead candidate, ATH434, targeting Parkinsonian disorders like Multiple System Atrophy. The company holds a strong patent portfolio around its proprietary iron-chaperone platform, which targets the underlying pathology of neurodegeneration. It is a clinical-stage biotechnology company addressing orphan drug indications with high unmet medical needs.

Loading...
PRICE (1Y)+5500.0%
0.010.110.210.320.42May 12Jun 2Jun 23
SMA 50SMA 200
Close
$0.39
RSI (14)
64.9
52W High
$0.61
From 52W High
0.6%

SCORE BREAKDOWN

Quality
38
ROIC
-29.0%23.4
ROE
-47.0%19.0
GP/Assets
14.1%33.4
Op. Margin
-372.6%10.9
FCF/Assets
-23.1%14.0
Piotroski
19.3
Int. Cover
—N/A
D/E Ratio
0.00x96.2
Current Ratio
21.98x96.2
Value
30
P/E (TTM)
—N/A
EV/EBITDA
-3.1x25.0
P/FCF
—N/A
P/B
1.8x63.0
P/S
14.7x20.5
Div Yield
—N/A
Momentum
29
52W High %
64%25.6
RS 6M
38%N/A
SMA 50/200
1.06x48.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$90M
P/E (Forward)
-0.2x
Gross Margin
97.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATH.AX are excluded.

TickerCompanyMkt CapStockRankSignal
ATH.AXAlterity Therapeutics Limited(you)$90M15STRONG SELL
ACW.AXActinogen Medical Limited$87M9STRONG SELL
OCC.AXOrthocell Limited$146M14STRONG SELL
LTP.AXLTR PHARMA FPO [LTP]$71M6STRONG SELL
DXB.AXDimerix Limited$92M1STRONG SELL
ILA.AXIsland Pharmaceuticals Limited$76M3STRONG SELL
NYR.AXNyrada Inc.$79M1STRONG SELL
PAR.AXParadigm Biopharmaceuticals Limited$70M0STRONG SELL
IMM.AXImmutep Limited$54M5STRONG SELL
RAC.AXRacura Oncology Ltd$330M10STRONG SELL

Peer medians: ROE -18.2% · P/E 21.1x · Gross margin 47.5%

Alterity Therapeutics Limited (ATH.AX) — Stock Score Summary

Alterity Therapeutics Limited (ATH.AX) has a MoatMap StockRank of 15/100 based on Quality (38/100), Value (30/100), and Momentum (29/100) factor scores. The current signal is STRONG SELL.

Alterity Therapeutics Limited develops disease-modifying therapies for neurodegenerative diseases, with its lead candidate, ATH434, targeting Parkinsonian disorders like Multiple System Atrophy. The company holds a strong patent portfolio around its proprietary iron-chaperone platform, which targets the underlying pathology of neurodegeneration. It is a clinical-stage biotechnology company addressing orphan drug indications with high unmet medical needs.

Key Financial Metrics

Price$0.39
Market Cap$90M
P/E (Forward)-0.18
Price/Book1.80
Return on Equity-47.0%
Return on Invested Capital-29.0%
Debt/Equity0.18
Gross Margin97.5%
Operating Margin-372.6%
Revenue Growth74.6%
Free Cash Flow$-5M

Alterity Therapeutics Limited operates in the Biotechnology industry, part of the Healthcare sector (Australia).

Frequently Asked Questions

What is Alterity Therapeutics Limited’s (ATH.AX) StockRank?
MoatMap’s StockRank for Alterity Therapeutics Limited (ATH.AX) is 15/100, with a Strong Sell signal. It is a composite of Quality (38), Value (30), and Momentum (29) factor ranks across MoatMap’s 20,000+ stock universe.
Does Alterity Therapeutics Limited have an economic moat?
Alterity Therapeutics Limited (ATH.AX) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Alterity Therapeutics Limited a buy, hold, or sell?
MoatMap’s current signal for Alterity Therapeutics Limited (ATH.AX) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Alterity Therapeutics Limited in?
Alterity Therapeutics Limited (ATH.AX) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).
Browse all ranked stocksATH.AX deep dive reportAI ChampionsHow we score stocksSense-check another stock